Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 74, Issue 8, Pages 1021-1028Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00228-018-2477-6
Keywords
Repaglinide; Irbesartan; Drug interactions; SLCO1B1; Polymorphism; Pharmacokinetics; Pharmacodynamics
Categories
Funding
- National Natural Science Foundation of China [81373490, 81573463, 81573508]
- National Key Research and Development Programs [2016YFC1306900, 2016YFC0905002, 2016YFC1201805]
- Strategy-Oriented Special Project of Central South University in China [ZLXD2017003]
- Hunan Natural Science Foundation [2017JJ3464]
Ask authors/readers for more resources
On account of the potential inhibition of OATP1B1 (organic anion transporting polypeptide) by angiotensin II receptor blockers (ARBs) and the effects of SLCO1B1 (solute carrier organic anion transporter family member) polymorphism, the aim of current study is to assess the impact of ARBs on the pharmacokinetics (PK) and pharmacodynamics (PD) of repaglinide in Chinese healthy volunteers with different SLCO1B1 genotypes. The in vitro study was conducted on irbesartan, valsartan, olmesartan, and losartan by using HEK293 cells transfected with OATP1B1. Data on drug interactions between repaglinide and irbesartan from 21 healthy Chinese-Han male volunteers were collected and analyzed. IC50 from in vitro study suggested irbesartan was the most potent inhibitor of OATP1B1 transporter. Clinical data from single dose of repaglinide indicated SLCO1B1 c.521 T > C polymorphism influenced the PK and PD of repaglinide in healthy Chinese-Han male volunteers. In subjects with SLCO1B1 c.521 TT genotype, irbesartan comedication increased the exposure of repaglinide. In details, the peak plasma concentration [C (max)] increased 84% (P = 0.003) and the area under the curve of plasma concentration 0-8 h [AUC(0-8)] increased 34% (P = 0.004), while the minimum blood glucose concentration [C (min)] decreased 33.8% (P = 0.005). No significant change was observed in repaglinide exposure in subjects with SLCO1B1 c.521 TC genotype in presence or absence of irbesartan. SLCO1B1 c.521 T > C polymorphism affects the PK of repaglinide in Chinese population. Irbesartan increased repaglinide exposure in subjects with SLCO1B1 c.521 TT genotype, but not SLCO1B1 c.521 TC genotype.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available